India: Pharma Delhi HC Issues Injunction against Sinopharm Weiqida
The Indian High Court has blocked the export, importation and sale of Sinopharm Weiqida’s amoxicillin active ingredient into India as it infringes the patent of Centrient Pharmaceuticals. The court also found the company guilty of Contempt of Court for failing to follow the previously granted preliminary injunction order.
Rotterdam/The Netherlands – Centrient, and its wholly owned subsidiaries, Centrient Pharmaceuticals Netherlands and Centrient Pharmaceuticals India, announced that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceutical Co. (Weiqida) blocking the export, importation and sale of its amoxicillin active ingredient into India. The injunction prevents the importation of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India in any form.
Weiqida was also found in contempt of the Delhi High Court’s original preliminary injunction order, granted in April 2017, through its continued importation and sale of its amoxicillin trihydrate active pharmaceutical ingredient in India. Centrient will seek monetary compensation for the damage sustained by the illegal shipments, in violation of the preliminary injunction since April 2017.
Centrient wishes to put all buyers of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India on notice (even if such API transits through India under advanced license) to be aware of the above orders of the Delhi High Court. Centrient shall ensure full compliance of the orders of the Delhi High Court and will notify the Indian Customs Authority and other authorities to seize all future Weiqida amoxicillin shipments at the relevant customs facilities.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 45756266)